SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Artemis Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘EX-31.1’

On:  Tuesday, 3/30/21, at 1:26pm ET   ·   For:  12/31/20   ·   Accession #:  1178913-21-1229   ·   File #:  0-24431

Previous ‘10-K’:  ‘10-K’ on 3/30/20 for 12/31/19   ·   Next:  ‘10-K’ on 3/3/22 for 12/31/21   ·   Latest:  ‘10-K/A’ on 5/3/23 for 12/31/22   ·   7 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/21  Artemis Therapeutics, Inc.        10-K       12/31/20   42:2M                                     Z-K Global Ltd./FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    317K 
 2: EX-31.1     Certification -- §302 - SOA'02 -- exhibit_31-1      HTML     17K 
 3: EX-32.1     Certification -- §906 - SOA'02 -- exhibit_32-1      HTML     14K 
10: R1          Document and Entity Information                     HTML     51K 
11: R2          Consolidated Balance Sheet                          HTML     72K 
12: R3          Consolidated Balance Sheet (Parenthetical)          HTML     33K 
13: R4          Consolidated Statement of Operation                 HTML     42K 
14: R5          Consolidated Statements of changes of               HTML     35K 
                shareholder's equity (Deficiency)                                
15: R6          Consolidated Statement of Cash Flows                HTML     45K 
16: R7          General                                             HTML     22K 
17: R8          Significant Accounting Policies                     HTML     27K 
18: R9          Commitments and Contingencies                       HTML     17K 
19: R10         Income Tax                                          HTML     42K 
20: R11         Warrants Issued to Investors                        HTML     19K 
21: R12         Computation of Net Loss per Share                   HTML     29K 
22: R13         Stock Capital                                       HTML     57K 
23: R14         Related Parties                                     HTML     17K 
24: R15         Subsequent Events                                   HTML     16K 
25: R16         Significant Accounting Policies (Policies)          HTML     49K 
26: R17         Income Tax (Tables)                                 HTML     38K 
27: R18         Warrants Issued to Investors (Tables)               HTML     20K 
28: R19         Computation of Net Loss per Share (Tables)          HTML     28K 
29: R20         Stock Capital (Tables)                              HTML     53K 
30: R21         Commitments and Contingencies (Details)             HTML     18K 
31: R22         Income Tax (Narrative) (Details)                    HTML     21K 
32: R23         Income Tax (Schedule of Deferred Income Taxes)      HTML     19K 
                (Details)                                                        
33: R24         Income Tax (Schedule of Net Operating Loss          HTML     18K 
                Carryforwards) (Details)                                         
34: R25         Warrants Issued to Investors (Details)              HTML     19K 
35: R26         Computation of Net Loss per Share (Schedule of      HTML     35K 
                Calculation of Basic Loss Per Share) (Details)                   
36: R27         Stock Capital (Narrative) (Details)                 HTML     42K 
37: R28         Stock Capital (Summary of Stock Option Activity)    HTML     41K 
                (Details)                                                        
38: R29         Stock Capital (Summary of Stock Option Exercise     HTML     30K 
                price) (Details)                                                 
39: R30         Related Parties (Narrative) (Details)               HTML     23K 
41: XML         IDEA XML File -- Filing Summary                      XML     71K 
40: EXCEL       IDEA Workbook of Financial Reports                  XLSX     40K 
 4: EX-101.INS  XBRL Instance -- atms-20201231                       XML    488K 
 6: EX-101.CAL  XBRL Calculations -- atms-20201231_cal               XML     70K 
 7: EX-101.DEF  XBRL Definitions -- atms-20201231_def                XML    211K 
 8: EX-101.LAB  XBRL Labels -- atms-20201231_lab                     XML    433K 
 9: EX-101.PRE  XBRL Presentations -- atms-20201231_pre              XML    325K 
 5: EX-101.SCH  XBRL Schema -- atms-20201231                         XSD     82K 
42: ZIP         XBRL Zipped Folder -- 0001178913-21-001229-xbrl      Zip     57K 


‘EX-31.1’   —   Certification — §302 – SOA’02 — exhibit_31-1


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 


EXHIBIT 31.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

I, Chanan Morris, certify that:

1.           I have reviewed this annual report on Form 10-K for the year ended December 31, 2020 of Artemis Therapeutics, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)         designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)         disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)          all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
 
(Principal Executive Officer and
Principal Financial Officer)
 



Dates Referenced Herein

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/30/21None on these Dates
For Period end:12/31/20
 List all Filings 


7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/19/19  Manuka, Inc.                      10-Q        6/30/19   43:2.4M                                   Z-K Global Ltd./FA
10/25/17  Manuka, Inc.                      8-K:1,3,5,910/25/17    4:558K                                   Z-K Global Ltd./FA
 8/29/16  Manuka, Inc.                      8-K:1,2,3,5 8/29/16    5:1M                                     Z-K Global Ltd./FA
 8/09/11  Artemis Therapeutics, Inc.        DEF 14A     8/09/11    1:626K                                   Z-K Global Ltd./FA
 9/24/10  Artemis Therapeutics, Inc.        8-K:5,9     9/24/10    5:52K                                    Z-K Global Ltd./FA
 4/04/08  Artemis Therapeutics, Inc.        8-K:5,9     4/04/08    2:5K                                     Z-K Global Ltd./FA
11/14/02  Artemis Therapeutics, Inc.        10QSB       9/30/02    6:113K                                   Bowne & C… Smartedgar/FA
Top
Filing Submission 0001178913-21-001229   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 8:28:15.2am ET